News
REGENXBIO Inc. (NASDAQ:RGNX) is one of the biotech stocks to buy according to Wall Street analysts. On July 10, REGENXBIO announced the publication of preclinical results for its investigational gene ...
The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
1d
Amazon S3 on MSNThe story of Sarepta's Duchenne gene therapyThe last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
Vinay Prasad, FDA's top vaccine official, has resigned after three months amid criticism and controversy, especially concerning the FDA's handling of a gene therapy for Duchenne muscular dystrophy.
After our editorial, the agency relents to allow a Duchenne treatment.
The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
3d
MedPage Today on MSNShipments of Duchenne Gene Therapy to Resume After FDA Review of Patient DeathSarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver ...
Sarepta Therapeutics said it will resume shipments of its gene therapy Elevidys® (delandistrogene moxeparvovec-rokl) “imminently” to ambulant patients with Duchenne muscular dystrophy (DMD), ending a ...
Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping ...
The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results